158 related articles for article (PubMed ID: 36493799)
1. Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT.
Polverelli N; Hernández-Boluda JC; Czerw T; Barbui T; D'Adda M; Deeg HJ; Ditschkowski M; Harrison C; Kröger NM; Mesa R; Passamonti F; Palandri F; Pemmaraju N; Popat U; Rondelli D; Vannucchi AM; Verstovsek S; Robin M; Colecchia A; Grazioli L; Damiani E; Russo D; Brady J; Patch D; Blamek S; Damaj GL; Hayden P; McLornan DP; Yakoub-Agha I
Lancet Haematol; 2023 Jan; 10(1):e59-e70. PubMed ID: 36493799
[TBL] [Abstract][Full Text] [Related]
2. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group.
Kröger N; Bacigalupo A; Barbui T; Ditschkowski M; Gagelmann N; Griesshammer M; Gupta V; Hamad N; Harrison C; Hernandez-Boluda JC; Koschmieder S; Jain T; Mascarenhas J; Mesa R; Popat UR; Passamonti F; Polverelli N; Rambaldi A; Robin M; Salit RB; Schroeder T; Scott BL; Tamari R; Tefferi A; Vannucchi AM; McLornan DP; Barosi G
Lancet Haematol; 2024 Jan; 11(1):e62-e74. PubMed ID: 38061384
[TBL] [Abstract][Full Text] [Related]
3. Splenic irradiation as a component of a reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly.
Ito T; Akagi K; Kondo T; Kawabata H; Ichinohe T; Takaori-Kondo A
Tohoku J Exp Med; 2012 Dec; 228(4):295-9. PubMed ID: 23117264
[TBL] [Abstract][Full Text] [Related]
4. Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: A global collaborative analysis.
Gagelmann N; Hobbs GS; Campodonico E; Helbig G; Novak P; Schroeder T; Schneider A; Rautenberg C; Reinhardt HC; Bosques L; Heuser M; Panagiota V; Thol F; Gurnari C; Maciejewski JP; Ciceri F; Rathje K; Robin M; Pagliuca S; Rubio MT; Rocha V; Funke V; Hamerschlak N; Salit R; Scott BL; Duarte F; Mitrus I; Czerw T; Greco R; Kröger N
Am J Hematol; 2024 May; 99(5):844-853. PubMed ID: 38357714
[TBL] [Abstract][Full Text] [Related]
5. [Successful management of splenomegaly with ruxolitinib prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis].
Fujishima M; Fujishima N; Kitadate A; Guo Y; Watanabe A; Ubukawa K; Nara M; Yoshioka T; Kameoka Y; Takahashi N
Rinsho Ketsueki; 2017; 58(7):743-748. PubMed ID: 28781268
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party.
McLornan DP; Hernandez-Boluda JC; Czerw T; Cross N; Joachim Deeg H; Ditschkowski M; Moonim MT; Polverelli N; Robin M; Aljurf M; Conneally E; Hayden P; Yakoub-Agha I
Leukemia; 2021 Sep; 35(9):2445-2459. PubMed ID: 34040148
[TBL] [Abstract][Full Text] [Related]
7. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation.
Ciurea SO; Sadegi B; Wilbur A; Alagiozian-Angelova V; Gaitonde S; Dobogai LC; Akard LP; Hoffman R; Rondelli D
Br J Haematol; 2008 Apr; 141(1):80-3. PubMed ID: 18324970
[TBL] [Abstract][Full Text] [Related]
8. Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT.
Nabergoj M; Mauff K; Robin M; Kröger N; Angelucci E; Poiré X; Passweg J; Radujkovic A; Platzbecker U; Robinson S; Rambaldi A; Petersen SL; Stölzel F; Stelljes M; Ciceri F; Mayer J; Ladetto M; de Wreede LC; Koster L; Hayden PJ; Czerw T; Hernández-Boluda JC; McLornan D; Chalandon Y; Yakoub-Agha I
Bone Marrow Transplant; 2021 Aug; 56(8):1944-1952. PubMed ID: 33824436
[TBL] [Abstract][Full Text] [Related]
9. Splenic pooling and loss of VCAM-1 causes an engraftment defect in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation.
Hart C; Klatt S; Barop J; Müller G; Schelker R; Holler E; Huber E; Herr W; Grassinger J
Haematologica; 2016 Nov; 101(11):1407-1416. PubMed ID: 27662011
[TBL] [Abstract][Full Text] [Related]
10. Enlarged spleen is associated with low neutrophil and platelet engraftment rates and poor survival after allogeneic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome.
Shimomura Y; Hara M; Katoh D; Hashimoto H; Ishikawa T
Ann Hematol; 2018 Jun; 97(6):1049-1056. PubMed ID: 29455235
[TBL] [Abstract][Full Text] [Related]
11. European wide survey on allogeneic haematopoietic cell transplantation practice for myelofibrosis on behalf of the EBMT chronic malignancies working party.
McLornan DP; Sirait T; Hernández-Boluda JC; Czerw T; Hayden P; Yakoub-Agha I
Curr Res Transl Med; 2021 Jan; 69(1):103267. PubMed ID: 33069640
[TBL] [Abstract][Full Text] [Related]
12. Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT).
Polverelli N; Mauff K; Kröger N; Robin M; Beelen D; Beauvais D; Chevallier P; Mohty M; Passweg J; Rubio MT; Maertens J; Finke J; Bornhäuser M; Vrhovac R; Helbig G; Mear JB; Castagna L; Reményi P; Angelucci E; Karakasis D; Rifòn J; Sirait T; Russo D; de Wreede L; Czerw T; Hernández-Boluda JC; Hayden P; McLornan D; Yakoub-Agha I
Am J Hematol; 2021 Jan; 96(1):69-79. PubMed ID: 33064301
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
[TBL] [Abstract][Full Text] [Related]
14. Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT.
Polverelli N; Bonneville EF; de Wreede LC; Koster L; Kröger NM; Schroeder T; Peffault de Latour R; Passweg J; Sockel K; Broers AEC; Clark A; Dreger P; Blaise D; Yakoub-Agha I; Petersen SL; Finke J; Chevallier P; Helbig G; Rabitsch W; Sammassimo S; Arcaini L; Russo D; Drozd-Sokolowska J; Raj K; Robin M; Battipaglia G; Czerw T; Hernández-Boluda JC; McLornan DP
Am J Hematol; 2024 May; 99(5):993-996. PubMed ID: 38385579
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry.
Hernández-Boluda JC; Pereira A; Kröger N; Cornelissen JJ; Finke J; Beelen D; de Witte M; Wilson K; Platzbecker U; Sengeloev H; Blaise D; Einsele H; Sockel K; Krüger W; Lenhoff S; Salaroli A; Martin H; García-Gutiérrez V; Pavone V; Alvarez-Larrán A; Raya JM; Zinger N; Gras L; Hayden P; Czerw T; P McLornan D; Yakoub-Agha I
Am J Hematol; 2021 Oct; 96(10):1186-1194. PubMed ID: 34152630
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes.
Chhabra S; Narra RK; Wu R; Szabo A; George G; Michaelis LC; D'Souza A; Dhakal B; Drobyski WR; Fenske TS; Jerkins JH; Pasquini MC; Rizzo RD; Saber W; Shah NN; Shaw BE; Hamadani M; Hari PN
Biol Blood Marrow Transplant; 2020 May; 26(5):893-901. PubMed ID: 31982543
[TBL] [Abstract][Full Text] [Related]
17. Nonfluorodeoxyglucose-Avid Persistent Splenomegaly at Time of Transplantation Delays Neutrophil and Platelets Engraftment without Affecting Survival in Patients with Lymphomas Undergoing Allogeneic Hematopoietic Cell Transplantation.
Khimani F; Jeong DK; Miladinovic B; Nishihori T; Ayala E; Locke F; Mishra A; Chavez J; Shah B; Gage K; Kharfan-Dabaja MA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2201-2207. PubMed ID: 27660169
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.
Jaekel N; Behre G; Behning A; Wickenhauser C; Lange T; Niederwieser D; Al-Ali HK
Bone Marrow Transplant; 2014 Feb; 49(2):179-84. PubMed ID: 24292520
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
Lussana F; Rambaldi A; Finazzi MC; van Biezen A; Scholten M; Oldani E; Carobbio A; Iacobelli S; Finke J; Nagler A; Volin L; Lamy T; Arnold R; Mohty M; Michallet M; de Witte T; Olavarria E; Kröger N
Haematologica; 2014 May; 99(5):916-21. PubMed ID: 24389309
[TBL] [Abstract][Full Text] [Related]
20. Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis.
Alchalby H; Yunus DR; Zabelina T; Ayuk F; Kröger N
Bone Marrow Transplant; 2016 Sep; 51(9):1223-7. PubMed ID: 27088376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
